Literature DB >> 7553472

Benefit of palliative surgery for bowel obstruction in advanced ovarian cancer.

P Jong1, J Sturgeon, C G Jamieson.   

Abstract

OBJECTIVES: To determine the benefit of palliative surgery for patients with advanced ovarian cancer and bowel obstruction and to identify criteria for selecting patients who are most likely to benefit from palliation.
DESIGN: A retrospective study of patients treated between 1982 and 1992.
SETTING: A university-affiliated hospital. PATIENTS: Fifty-three patients with complete and unresolved bowel obstruction caused by ovarian cancer. INTERVENTION: Surgery for relief of bowel obstruction. MAIN OUTCOME MEASURES: Postoperative survival longer than 60 days, return home and relief of bowel obstruction for longer than 60 days, factors associated with failure of palliative surgery.
RESULTS: Successful palliation was achieved in 27 (51%) patients and was associated with the absence of four prognostic factors: palpable abdominal and pelvic masses, ascites exceeding 3 L, multiple obstructive sites and preoperative weight loss greater than 9 kg. Age, time interval between diagnosis of ovarian cancer and bowel obstruction, stage of disease at initial diagnosis, tumour type and grade, site and degree of obstruction, presence of gross residual tumour after initial operation and preoperative use of chemotherapy or radiotherapy did not indicate the success or failure of palliative surgery.
CONCLUSIONS: Palliative surgery for bowel obstruction in advanced ovarian cancer can be worthwhile, and there are four prognostic factors that indicate the likely failure of palliation.

Entities:  

Mesh:

Year:  1995        PMID: 7553472

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  11 in total

Review 1.  Salvage therapy for ovarian cancer.

Authors:  A A Garcia
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

2.  [Palliative symptom control in malignant bowel obstruction due to advanced ovarian cancer].

Authors:  Kurt Alker; Franz Harnoncourt
Journal:  Wien Med Wochenschr       Date:  2006-05

Review 3.  Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer.

Authors:  Sarah E Cousins; Emma Tempest; David J Feuer
Journal:  Cochrane Database Syst Rev       Date:  2016-01-04

Review 4.  The role of palliative surgery in gynecologic cancer cases.

Authors:  Joanie Mayer Hope; Bhavana Pothuri
Journal:  Oncologist       Date:  2013-01-08

Review 5.  The role of parenteral nutrition in patients with malignant bowel obstruction.

Authors:  Federico Bozzetti
Journal:  Support Care Cancer       Date:  2019-07-17       Impact factor: 3.603

6.  Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer.

Authors:  Rudy S Suidan; Weiguo He; Charlotte C Sun; Hui Zhao; Lois M Ramondetta; Brian D Badgwell; Diane C Bodurka; Karen H Lu; Sharon H Giordano; Larissa A Meyer
Journal:  Int J Gynecol Cancer       Date:  2017-09       Impact factor: 3.437

Review 7.  Malignant Bowel Obstruction Management Over Time: Are We Doing Anything New? A Current Narrative Review.

Authors:  Farhana Shariff; Jessica Bogach; Keegan Guidolin; Ashlie Nadler
Journal:  Ann Surg Oncol       Date:  2021-10-18       Impact factor: 5.344

Review 8.  Surgical management of malignant bowel obstruction: strategies toward palliation of patients with advanced cancer.

Authors:  Robert DeBernardo
Journal:  Curr Oncol Rep       Date:  2009-07       Impact factor: 5.075

Review 9.  Palliative surgery for malignant bowel obstruction from carcinomatosis: a systematic review.

Authors:  Terrah J Paul Olson; Carolyn Pinkerton; Karen J Brasel; Margaret L Schwarze
Journal:  JAMA Surg       Date:  2014-04       Impact factor: 14.766

10.  Small bowel obstruction in patients with a prior history of cancer: predictive findings of malignant origins.

Authors:  J Prost À la Denise; R Douard; G Malamut; F Mecheri; P Wind
Journal:  World J Surg       Date:  2014-02       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.